期刊
FRONTIERS IN ONCOLOGY
卷 11, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.777617
关键词
angiogenesis; gallbladder carcinoma; biliary tract cancers; cholangiocarcinoma; targeted therapy; mechanism; antiangiogenic therapy
类别
资金
- Shandong University Multidisciplinary Research and Innovation Team of Young Scholars [2020QNQT002]
- National Natural Science Foundation of China [82072676, 82172791]
- China Postdoctoral Science Foundation [2020M682190, 2020M682195]
- Clinical Research Foundation of Shandong University [2020SDUCRCA018]
- Natural Science Foundation of Shandong Province [ZR2019MH008]
- Jinan City Science and Technology Development Program [201805017, 201805013]
- Clinical Research Innovation Fund Project [CXPJJH11800001-2018240]
- Hengrui Hepatobiliary and Pancreatic Foundation
- Beijing Medical Award Foundation [YXJL-2020-0785-0967, YXJL-2020-0785-0968]
The article summarizes the latest advances in antiangiogenic therapy for biliary tract cancers, focusing on the molecular mechanisms and therapeutic effects, while highlighting the uncertainty surrounding the effectiveness of antiangiogenic therapy.
Biliary tract cancers (BTCs), including cholangiocarcinoma (CCA) and gallbladder cancer (GC), are malignancies originating from the biliary tract with poor prognosis. In the early stage of BTCs, surgery is the only choice for cure. Unfortunately, most patients with BTC are diagnosed at an advanced stage and lose the opportunity for surgery. For many advanced solid tumors, antiangiogenic therapy has achieved encouraging results. While most clinical studies on antiangiogenic therapy in advanced BTCs have shown an excellent disease control rate (DCR), the improvement in overall survival (OS) is controversial. Understanding how the relevant signaling molecules influence the angiogenic response and the functional interaction is necessary for the formulation of new treatment regimens and the selection of enrolled patients. In this review, we aim to summarize and discuss the latest advances in antiangeogenesis for BTCs, mainly focusing on the molecular mechanism of angiogenesis in BTCs and the therapeutic effects from clinical trials. Furthermore, the horizon of antiangiogenesis for BTCs is highlighted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据